Position paper--PUVA therapy. American Academy of Dermatology.
PUVA, the combination of psoralen (P) and long-wave ultraviolet radiation (UVA), is being used increasingly in the management of psoriasis and several other dermatologic disorders. While the acute toxicity of this modality, which includes erythema and blistering of the skin, can be avoided with careful monitoring of the dosimetry of the administered radiation, the potential chronic toxicity remains a source of concern. Since psoralens and UVA are clearly mutagenic, carcinogenic, cataractogenic, and may have as yet poorly understood effects on the immune system, it is imperative that all patients treated with this modality be carefully monitored for the development of neoplasia and cataracts. PUVA therapy should only be administered using specialized equipment that can be accurately monitored for its spectral irradiance by physicians thoroughly familiar with the risks and benefits of the modality.
D002386:Cataract / Q000209:etiology; D002986:Clinical Trials as Topic; D003362:Cost-Benefit Analysis; D005500:Follow-Up Studies; D006801:Humans; D007153:Immunologic Deficiency Syndromes / Q000209:etiology; D009182:Mycosis Fungoides / Q000628:therapy; D011701:PUVA Therapy / Q000009:adverse effects; D010778:Photochemotherapy; D011565:Psoriasis / Q000628:therapy; D012306:Risk; D012871:Skin Diseases / Q000628:therapy; D012878:Skin Neoplasms / Q000209:etiology / Q000628:therapy; D013997:Time Factors